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Skin  has  gained  substantial  attention  as  a  vaccine  target  organ  due  to  its immunological  properties,  which
include  a high  density  of professional  antigen  presenting  cells  (APCs).  Previous  studies  have  demonstrated
the effectiveness  of  this  vaccination  route  not  only  in  animal  models  but also  in  adults.  Young  children
represent  a  population  group  that  is  at high  risk  from  inﬂuenza  infection.  As a result,  this group  could  ben-
eﬁt signiﬁcantly  from  inﬂuenza  vaccine  delivery  approaches  through  the  skin  and  the  improved  immune
response  it  can  induce.  In this  study,  we compared  the  immune  responses  in young  BALB/c  mice  upon
skin delivery  of  inﬂuenza  vaccine  with  vaccination  by  the  conventional  intramuscular  route.  Young  mice
that  received  5 g of H1N1  A/Ca/07/09  inﬂuenza  subunit  vaccine  using  MN  demonstrated  an  improved
serum  antibody  response  (IgG1  and  IgG2a)  when  compared  to the  young  IM  group,  accompanied  by
higher  numbers  of inﬂuenza-speciﬁc  antibody  secreting  cells  (ASCs)  in  the  bone  marrow.  In addition,
we  observed  increased  activation  of follicular  helper  T  cells  and  formation  of germinal  centers  in the
regional  lymph  nodes  in  the MN immunized  group,  rapid  clearance  of  the  virus  from  their  lungs  as  well
as  complete  survival,  compared  with  partial  protection  observed  in  the  IM-vaccinated  group.  Our  results
support  the hypothesis  that  inﬂuenza  vaccine  delivery  through  the  skin  would  be beneﬁcial  for  protecting
the  high-risk  young  population  from  inﬂuenza  infection.
©  2015  Published  by Elsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  license. Introduction
Inﬂuenza virus is one of the most common respiratory
athogens and one of the most frequent causes of upper respiratory
ract infection [1]. When infection occurs in adults, the course of the
llness is often mild and self-limited, without the need for medical
are or antiviral drugs in most cases, and the expected recovery
ime is less than two weeks [2,3]. There are however groups at high
isk from inﬂuenza infection, in which the disease severity is much
reater than that observed in adults. These include the elderly over
∗ Corresponding author at: Department of Microbiology & Immunology, Emory
niversity School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, United States.
el.: +1 404 727 2015; fax: +1 404 727 3295.
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ttp://dx.doi.org/10.1016/j.vaccine.2015.01.086
264-410X/© 2015 Published by Elsevier Ltd. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/3.0/).
65 [4,5], persons with underlying chronic diseases [6,7], infants and
children 5 years of age and younger who have not been previously
exposed to the virus [8,9], and pregnant women [10,11]. Inﬂuenza
infection among these groups is often followed by secondary com-
plications such as sinus infection, bronchitis, pneumonia as well as
failure of other organs such as the heart and the kidneys, occasion-
ally resulting in death [12,13]. Infants and children 5 years of age
and younger represent one of the most susceptible groups and have
increased mortality rates [2,14].
Annual vaccination is the most effective method of protection
against inﬂuenza infection [15]. Despite recommendations for vac-
cination targeted to high-risk groups and their contacts, the CDC
estimates that 36,000 deaths and 1.7 million hospitalizations can
be attributed to seasonal inﬂuenza infection annually in the U.S.
[16,17], with highest disease severity and mortality among high-
risk groups [18,19]. While inﬂuenza vaccines can be highly effective
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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n adults, there are reduced beneﬁts in young children leaving them
ulnerable to infection [20,21]. Live attenuated inﬂuenza vaccine
LAIV) is not approved for children under 2 due to safety concerns
22,23]. Several studies have demonstrated the limited ability of
nactivated inﬂuenza vaccine to induce strong humoral and cellu-
ar immune responses in young children, potentially because of the
mmaturity of their immune system as well as lack of prior exposure
o inﬂuenza viral antigens [24–26]. As a result of reduced protec-
ion, the CDC issued new guidelines recommending 2 or more doses
f seasonal inﬂuenza vaccine for this age group. This approach,
owever, can be associated with compliance and timeline issues
hich limit the desired results. These factors support the need for
ew vaccine formulations and alternative vaccination routes that
ill increase compliance, and improve protective immunity, in this
igh-risk population [27,28].
Several studies have demonstrated that delivery of inﬂuenza
accine through the skin of adult mice, using different types of
icroneedle patches (MN), leads to enhanced immune responses
nd improved duration of protective immunity when compared to
onventional intramuscular delivery (IM) [29–31]. Because of these
romising results, and other studies [32,33] that demonstrated
mproved immune responses in humans after intradermal deliv-
ry of inﬂuenza antigen using reduced doses, the skin has gained
ttention as an attractive target for vaccine delivery.
Here we investigate delivery of a single dose of subunit inﬂuenza
accine through the skin with microneedle patches in 2 week old
ice and compare the results to those observed in young mice
mmunized through the conventional intramuscular route. The
esults support the advantages of skin vaccination using inﬂuenza
accines not only for adults but also for infants and young children,
ighlighting new vaccination strategies that will improve protec-
ive immunity.
. Materials and methods
.1. Microneedle fabrication and coating
As previously described [29] metal microneedles were fab-
icated by laser etching stainless steel sheets (McMaster-Carr,
tlanta, GA). Each microneedle measured 700 m tall, with a cross
ectional area of 170 m by 55 m at the base and tapering to a
harp tip, with ﬁve microneedles per row. The size of microneed-
es was selected based on the depth of skin antigen presenting
ell populations that are targeted for vaccine delivery and optimal
mmune response [34]. Microneedles were dip-coated as described
31].
.2. Cells and viruses
MDCK cells were maintained in Dulbecco’s Modiﬁed Eagle’s
edium (DMEM) (Mediatech, Herndon, VA) containing 10% fetal
ovine serum (Hyclone, Rockford, IL). Inﬂuenza virus stocks
A/California/07/2009) were prepared, puriﬁed and inactivated as
reviously described [30]. Hemagglutination (HA) activity was
etermined using turkey red blood cells (LAMPIRE, Pipersville, PA).
ouse-adapted virus was prepared by serial passage 8 times in
ungs of BALB/c mice. The LD50 was calculated by the method of
eed&Muench, and viral titer was determined by plaque assay
29,30].
.3. Immunizations and characterization of immune responsesFemale BALB/c mice (Charles River, Wilmington, MA)  (20 mice
er group, 2 weeks old) received one dose (5 g) of a licensed
ubunit A/California/07/2009 vaccine (obtained from Novartis
harmaceuticals) through the skin using antigen-coated MN arrayse 33 (2015) 4675–4682
or IM injection as described [31]. The sites of immunization for
both MN and IM delivery were the upper gluteal quadrants of both
legs and near the dorsal side. Animals were bled retro-orbitally
2 and 4 weeks post-immunization under systemic anesthe-
sia. Anti-Ca/07/09 speciﬁc IgG, IgG1, and IgG2a antibody levels
were determined quantitatively by enzyme-linked immunosor-
bent assay (ELISA) as described [35]. The 96-well plates were coated
with 2 g of subunit A/Ca/07/09 vaccine. Puriﬁed mouse IgG, IgG1,
and IgG2a and goat anti-mouse-HRP for ELISA were purchased from
Southern Biotechnology Associates (Birmingham, AL). Optical den-
sity was  read at 490 nm.  We  determined the hemagglutination
inhibition (HAI) titers based on the WHO  protocol as described
previously [35]. Heat-inactivated sera were treated with receptor-
destroying neuraminidase (RDE) (Roche Diagnostics, Indianapolis,
IN) overnight at 37 ◦C, heat inactivated for 30 min  at 56 ◦C and
incubated with packed turkey RBC for 1 h at 4 ◦C to remove any
cryoglobulins interfering with the agglutination reaction. They
were serially diluted and pre-incubated at room temperature with
4 HA Units/50 l of A/Ca/07/09 virus for 30 min. An equal volume
of 0.5% turkey red blood cells was  then added to each well for
30 min  incubation at room temperature. The HAI titer was  read
as the reciprocal of the highest dilution of serum that conferred
inhibition of hemagglutination. The values were expressed as the
geometric mean ± standard deviation.
Virus microneutralization assay was performed as described
previously [CDC Inﬂuenza manual Rev 06FEB98] with modiﬁca-
tions [31]. Brieﬂy, 50 ml  of virus diluent containing 100 xTCID50
of each virus was incubated with 50 ml  of serially diluted heat-
inactivated sera at 37 ◦C for 1 h, and then mixed with 100 ml  of
freshly trypsinized low-passage MDCK cell suspension (ATCC #
CRL-2936) containing 50,000 cells per well in 96-well tissue plates.
The controls wells contained cells alone (negative control) and cells
infected with virus (positive control). Following an 18–22 h incu-
bation period the cells were ﬁxed with acetone and the infected
wells were detected by ELISA. Mouse monoclonal biotinylated
anti-NP antibody MAB8257B (Millipore, Temecula, CA), and HRP-
streptavidin conjugate (BD # 51-9000209, BD Biosciences, San Jose,
CA), were used in the ELISA. Color was  developed using OPD sub-
strate (#002003 Invitrogen, Frederick, MD)  and optical density was
measured at 490 nm in plate reader (model 680 BioRad, Hercules,
CA). The highest serum dilution that generated 50% speciﬁc signal
was considered to be the neutralization titer; 50% speciﬁc signal =
(OD490 virus control - OD490 cell control)/2 + OD490 cell control.
One month post-immunization, mice (n = 5) were challenged
with 5xLD50 of mouse-adapted H1N1 A/California/07/2009 virus
and were monitored for 14 days for signs of morbidity (body weight
changes, fever and hunched posture) and mortality. Weight loss
exceeding 25% was used as the experimental end point, at which
mice were euthanized according to IACUC guidelines. The mouse-
adapted virus was produced by 8 serial passages in mouse lungs.
One month post immunization and four days post-challenge of
an independent cohort, lungs were collected to determine levels
of viral replication, and bone marrow was collected to determine
inﬂuenza-speciﬁc IgG, IgG1 and IgG2a antibody-secreting cells
(ASC) by ELISPOT [29]. Lung viral titers were measured per gram
of tissue from lunch homogenates prepared in DMEM serum-free
medium as previously described [35]. For ELISPOT assay, 96-well
plates were coated overnight at 4 ◦C with subunit A/Ca/07/09 vac-
cine at a ﬁnal concentration of 2 g/ml. The plates were washed
three times with RPMI medium and blocked for 2 h with 10% fetal
calf serum prior to sample addition. Single cell suspensions from
bone marrow collected at 4 days after challenge (0.5–1 × 106/well)
in cRPMI medium were plated directly on coated blocked plates and
were incubated at 37 ◦C for 16 h. Virus-speciﬁc ASC were detected
as spots after incubation with goat anti-mouse IgG horseradish
peroxidase (Southern Biotechnology) and developed with stable
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Fig. 1. Comparison of humoral immune responses induced by skin vs. intramuscular immunization. Serum samples from 2 week old mice were collected at 2 and 4
weeks  post immunization and analyzed for the levels of functional antibody titers against A/California/07/09 by HAI (A), total serum IgG titers (B), and the IgG isotypes, IgG1
(C)  and IgG2a (D) by quantitative ELISA. MN adult: adult microneedle immunized group, IM adult: adult intramuscularly immunized group MN  young: young microneedle
immunized group, IM young: young intramuscularly immunized group. ELISA antibody results represent the mean ± SD. The HAI titers were read as the reciprocal of the
highest  dilution of serum that conferred inhibition of hemagglutination. *p < 0.05, **p < 0.005, ***p < 0.0001.
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he results shown as the number of ASC per 106 cells [35].
Regional (inguinal) lymph nodes and spleens were collected 7
ays and 14 days post-vaccination for the evaluation of activated
ollicular T helper cells and germinal center formation by FACS. Sin-
le cell suspensions were incubated with Fc-block (2.4G2) on ice
or 15 min  before staining with PNA-FITC, Fas-PE, PD-1-PE-Texas
ed, CXCR5-APC, CD44-APC-e780, CD19-e450, CD4-BV510, CD3-
V650, and CD8-BV785 antibodies for 30 min  on ice. Antibodies
ere purchased from BD Biosciences, eBiosciences, and BioLegend.
ells were washed and ﬁxed in 1% paraformaldehyde for 30 min
t room temperature prior to analysis. Samples were acquired
n a LSR II ﬂow cytometer (BD Biosciences) and data were ana-
yzed with FlowJo software (Tree Star). Serum samples and lung
omogenates were individually processed to determine humoral
mmune responses and neutralization titers respectively. All ani-
al  studies had approval of Emory’s Institutional Animal Care and
se Committee.
.4. Statistics
The statistical signiﬁcance of differences was calculated by two-
ailed unpaired Student’s t-test and one-way ANOVA (one-way
nalysis of variance including Bonferroni’s multiple comparison
est) or two-way ANOVA. Values of p ≤ 0.05 were considered sig-
iﬁcant. Unless otherwise stated, independent experiments were
un at least in triplicate.3. Results
3.1. Humoral immune responses after MN or IM delivery of
inﬂuenza subunit vaccine
In order to assess the effectiveness of inﬂuenza vaccination in
young populations, we  ﬁrst measured the levels of functional anti-
body titers against the hemagglutinin antigen (HA) of inﬂuenza
virus induced after the skin delivery with MNs  or intramuscularly
immunization. Although no signiﬁcant responses were measured
as soon as day 14, young mice that received inﬂuenza subunit
vaccine through the skin using MN  patches demonstrated signiﬁ-
cantly higher HAI titers at day 28 post vaccination when compared
to IM-immunized young mice (Fig. 1A). The HAI  titers in young
mice that were immunized through the skin were similar to the
HAI titers measured in control immunized adult mice vaccinated
with either IM or MN routes. In addition, these results were fur-
ther supported by signiﬁcantly higher microneutralization titers
measured in serum samples from MN immunized young mice 28
days post-vaccination (supplementary Fig. 1). These results indi-
cate that delivery of subunit inﬂuenza vaccine through the skin
using MN patches in young mice induces higher levels of functional
antibodies when compared to IM immunization.
We furthermore determined the levels of inﬂuenza-speciﬁc cir-
culating IgG antibodies in sera of young mice vaccinated by either
MN or IM routes. At two and four weeks post-vaccination, young
mice that were immunized via the skin exhibited signiﬁcantly
higher total anti-inﬂuenza speciﬁc antibody titers when compared
to mice immunized IM (Fig. 1B). We  also measured signiﬁcantly
4678 D.G. Koutsonanos et al. / Vaccine 33 (2015) 4675–4682
Fig. 2. Protective efﬁcacy of immunization against H1N1 A/California/07/2009 lethal infection and analysis of lung viral titers. Body weight changes (A) and survival
rates  (B) were recorded after lethal challenge with 5xLD50 of A/California/07/2009 virus in young MN and IM immunized mice 2 weeks post immunization and naïve mice.
Lung  viral titers (C) were determined by plaque assay. INF: infected mice. Data represent the mean ± SD, *p < 0.05, **p < 0.005, ***p < 0.0001.
h
c
c
(
b
l
m
d
i
o
[
t
a
d
c
d
c
[
w
r
y
c
I
3
r
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inated by MN which were 2 or 3-fold higher respectively when
ompared to young mice that were immunized via the IM route
Fig. 1C and D). A signiﬁcant ﬁnding is the low levels of IgG2a anti-
odies measured in IM vaccinated mice, which could indicate the
ack of development of this arm of the immune system in young
ice after IM immunization. Several studies have demonstrated the
istinct contribution and important roles these isotypes play dur-
ng protection. We  have previously demonstrated that the proﬁle
f the immune responses is affected by the route of immunization
29,30]. In this study, young mice that received the subunit vaccine
hrough the MN  route exhibited similar levels of IgG2a antibodies
s found in adult mice immunized by MN.  Although no signiﬁcant
ifference in immune response was observed in IM vs. MN vac-
inated adult mice 28 days post-vaccination, we have previously
emonstrated the effectiveness of MN  delivery of inﬂuenza vac-
ine to induce improve immune responses that are long lasting
29]. Overall, the immune response in young mice after MN  delivery
as similar to that seen in adults after IM or MN  vaccination. These
esults indicate that MN  delivery of inﬂuenza subunit vaccine in
oung mice induces higher anti-inﬂuenza speciﬁc antibodies when
ompared to the titers observed in young mice immunized by the
M route, and a more closely balanced isotype antibody response.
.2. Protection against lethal inﬂuenza infectionIn order to compare the protective capacity of the immune
esponse induced in young mice after delivery of inﬂuenza sub-
nit vaccine by MN  or IM delivery, we challenged mice fromboth groups with 5xLD50 of mouse adapted H1N1 A/Ca/07/09
virus by intranasal inoculation with 50 l of the virus. After chal-
lenge, all mice were followed for 14 days for signs of morbidity
(body weight changes, fever and hunched posture) and mortal-
ity. As seen in Fig. 2A, young mice immunized by the IM route
exhibited a higher body weight loss when compared to the body
weight changes in young mice immunized via the skin. Addi-
tionally, young mice immunized IM were only partially protected
after lethal challenge, with a mortality rate of 40%. In contrast,
young mice that were immunized via the skin with MN patches
demonstrated 100% survival (Fig. 2B). The improved protection
observed in the young MN immunized mice is reﬂected by reduced
virus titers measured in the lungs of these mice one month post
vaccination and 4 days post challenge. In young mice that were
immunized by the IM route, we observed high virus titers with
a 1 log decrease when compared to unimmunized infected ani-
mals (Fig. 2C). In contrast, young MN-immunized mice exhibited
a 4 log decrease in lung virus titers when compared to the unim-
munized group. Although delivery of inﬂuenza vaccine using MN
patches conferred completed survival, mice from both MN and IM
immunized groups exhibited signs of disease with more intense
symptoms in the IM group. This is not surprising since both MN
and IM immunization represent systemic routes of vaccine deliv-
ery not capable of inducing sterilizing immunity, which can be
induced by intranasal vaccination [36]. These results demonstrate
the induction of more effective protective immune responses after
MN delivery of subunit inﬂuenza vaccine in young mice, and a
rapid clearance of the virus from their lungs, leading to complete
survival.
D.G. Koutsonanos et al. / Vaccine 33 (2015) 4675–4682 4679
Fig. 3. Comparison of bone marrow plasma cell levels after IM or MN immunization. The numbers of inﬂuenza-speciﬁc IgG (A) and IgG1 (B) and IgG2a (C) plasma cells in
the  bone marrow were determined by ELISPOT 4 weeks after a single immunization. The cells were cultured in the presence of 4 g/ml subunit A/California/07/2009 vaccine
and  16 h later the numbers of plasma cells in the bone marrow from young MN and IM vaccinated mice, adult MN and IM vaccinated mice and unvaccinated mice were
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aïve  mice. Data represent the mean ± SD, *p < 0.05, **p < 0.005, ***p < 0.0001.
.3. Evaluation of long-lived bone marrow plasma cells
To further investigate the improved immune responses when
ompared to IM immunization, we measured the levels of long-
ived inﬂuenza virus-speciﬁc IgG plasma cells in the bone marrow
nd IgG1 and IgG2a isotypes at 4 weeks after a single vaccination.
oung mice that received the vaccine through the skin via MNs
xhibited a two-fold higher number of IgG ASCs in the bone marrow
hen compared to the numbers measured in the IM group (Fig. 3A).
urthermore, we observed signiﬁcantly higher numbers of IgG1
p < 0.005) ASCs in the MN  group when compared to IM,  and three-
old higher levels of IgG2a ASCs in the young mice immunized via
N in comparison to IM immunized mice (Fig. 3B and C). The levels
f ASCs in the young mice immunized with MN  patches were sim-
lar to levels measured in MN  vaccinated adult mice controls. The
ncreased numbers of inﬂuenza virus-speciﬁc long-lived plasma
ells in the bone marrows of young mice vaccinated by MNs  corre-
ate with the higher serum antibody levels observed in these mice,
nd also correspond with the isotype difference observed between
N and IM vaccinated young mice. These differences reﬂect the
mproved humoral immune responses in young MN  mice and the
ifferences in protection observed among these groups after lethal
nﬂuenza challenge.
.4. Cellular immune responses in the lungs and spleens of
accinated young miceThe levels of CD4+ and CD8+ IFN- T-cells in the lungs and
pleens of young mice vaccinated by MN  or IM were also evalu-
ted. No signiﬁcant increase was measured in either of the two
-cell populations in the lungs of both MN  and IM young vaccinatedbers of spots were higher than the sum of naïve infected group spots + 3xSDev. N:
groups (supplementary Fig. 2A and B). Similarly, characterization of
CD4+ and CD8+ T-cells in the spleens of young mice did not reveal
signiﬁcant cellular immune responses (supplementary Fig. 2C and
D). Both MN and IM young mice vaccinated with inﬂuenza sub-
unit vaccine demonstrated reduced numbers of CD4+ and CD8+
T-cells when compared to the levels measured in adult MN  vacci-
nated mice (data not shown). These results indicate that in young
mice, delivery of subunit inﬂuenza vaccine induces a limited activa-
tion of the cellular response and that the protection observed after
challenge is mediated by humoral responses.
3.5. Evaluation of activated follicular B helper T (Tfh) cells and
germinal center formation
Several studies have demonstrated the fundamental role of
TFH cells for the generation of adaptive immunity, immunolog-
ical memory and the formation of germinal centers (GCs). We
measured a two-fold increase in the numbers of double-positive
CD4+ and CD44high T cells in the inguinal lymph nodes of young
mice immunized via the MN route when compared to the numbers
observed in the IM immunized group (Fig. 4B). GCs are formations
within secondary lymphoid organs in which the B cell response
against an antigen occurs. We  detected elevated numbers of dou-
ble positive FAS and PNA CD19 positive lymphocytes (activated
GCs) in regional lymph nodes of young mice immunized via MN
patches and a 3-fold increase when compared to the numbers
measured in young mice immunized via the IM route (Fig. 4A).
These results indicate that delivery of inﬂuenza subunit vaccine via
the skin with MN patches enhances TFH cell levels and increases
formation of GCs, leading to an improved antigen-speciﬁc B cell
response.
4680 D.G. Koutsonanos et al. / Vaccine 33 (2015) 4675–4682
Fig. 4. Analysis of activated follicular B helper T cells and germinal center formation. The numbers of GCs (A) and Tfh cells (B) from the inguinal lymph nodes were
determined by FACS analysis 7 days post immunization in 2-week-old mice vaccinated with microneedles or intramuscularly. Data represent the mean ± SD, *p < 0.05,
**p  < 0.005, ***p < 0.0001.
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Skin is the largest immunological organ of the human body [37].
t is composed of two primary layers, the epidermis and dermis [38].
n both layers, populations of specialized APCs with unique pheno-
ypic and functional roles are present: Langerhans cells (LCs) are
bundant in the epidermis and dermal dendritic cells (dDCs) are
nriched in the dermis [39–42]. These two populations can be dis-
inguished based on their surface markers: LCs express CD207 and
D205 and differential levels of CD11b, while dDCs express CD11b
nd CD205, but not CD207 [43,44]. Additionally, these two cell
opulations are characterized by differences in chemokine receptor
xpression and cytokine release [45].
This is the ﬁrst study, to our knowledge, that demonstrates
mproved immune responses and improved protection in young
ice after delivery of an inﬂuenza vaccine through the skin using
N patches. It has been estimated that each year, inﬂuenza infec-
ion in the U.S. is responsible for more than 20,000 childhood
ospitalizations and more than 100 pediatric deaths. Despite the
ncreased risk from infection, vaccination rates remain low with an
verage rate of 40% annually. These data strongly support the need
or new, more effective inﬂuenza vaccines or vaccination routes
hat can induce improved immune responses and protection, and
ncreased vaccine compliance and vaccination coverage in this high
isk group. Multiple factors could be responsible for reduced T cell
ctivation, reduced activation of GCs and an overall reduction in
daptive immune responses [29]. The skin represents an ideal tar-
et organ for vaccine delivery because it contains a large network of
rofessional APCs that will take up antigen and migrate to the prox-
mal lymph nodes to activate T and B cells, initiating the adaptive
mmune responses. Previous studies from our group and other havedemonstrated the immunological advantages after skin delivery of
inﬂuenza vaccine in adults [29,30]. In the present study, we demon-
strate improved humoral immune responses after skin delivery of a
single dose of inﬂuenza subunit vaccine using microneedle patches
in young mice, when compared to intramuscular immunization.
These improved humoral responses observed in young mice cor-
related with higher numbers of antibody-secreting cells in their
bone marrow. Germinal centers are formations within secondary
lymphoid organs where the process of B cell differentiation, pro-
liferation, maturation, clone selection and class switch is occurring
[46]. The processes taking place inside germinal centers will deﬁne
the quality of the B cell response to a speciﬁc antigen [47]. In this
process, B cells constantly migrate between the light and dark zones
within germinal centers during which the selection of long-lived B
cells with high afﬁnity for the antigen will occur [48]. The higher
number of activated GCs measured in the inguinal lymph nodes of
young mice 7 days post skin vaccination with inﬂuenza subunit vac-
cine correlates with the increased numbers of ASCs and improved
humoral immune responses observed in this group, when com-
pared to the intramuscularly immunized young mice, and may
be responsible for the more rapid virus clearance and complete
survival seen after lethal challenge. TFH cells are essential for the
regulation of B cell differentiation into plasma cells and memory B
cells thus playing a fundamental role in the generation of immuno-
logical memory [49,50]. TFH cells play a critical role in mediating
the selection of B cells and regulating their survival. These selected
B cells will further differentiate into high afﬁnity antibody secret-
ing cells (ASCs) or memory B cells that will be rapidly re-activated
upon encounter with a similar antigen [51]. We  observed increased
numbers of TFH cells in the proximal lymph nodes of young mice
immunized via microneedles, which are probably the result of
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etter antigen processing and presentation by antigen-presenting
ells residing in the dermis and epidermis.
The signiﬁcant differences observed in responses to the two
outes of immunization used in young mice validate the use of
his model, and support previous results showing the beneﬁts
f skin delivery of inﬂuenza vaccine using microneedle patches
29,31]. In addition to immunological advantages, microneedle skin
accination offers logistical advantages, such as ease of administra-
ion, rapid transport and delivery, lack of a requirement for highly
rained personnel to administer the vaccine as needed for intra-
uscular injection, and little or no bio-hazardous waste [30]. In
ontrast, the currently used intramuscular vaccination approach
elivers the vaccine to the muscle, an area with reduced num-
ers of APCs to take up and process the antigen, leading to reduced
mmune responses [29,52]. Furthermore, recent studies among vol-
nteers have demonstrated a preference for this route of vaccine
elivery over the conventional IM route [53]. Several factors might
ontribute to this preference, such as needle phobia, lack of pain,
nd the potential for self-administration. These factors could also
lay a crucial role in improving inﬂuenza vaccine compliance and
overage among the population [53]. Although in our study the
N  patches only contained one inﬂuenza strain, it is highly likely
hat MN delivery of the trivalent or quadrivalent vaccine will have
lso enhance the immune response. Previous studies that com-
ared the magnitude of the immune response when delivering a
ingle inﬂuenza strain, or multiple inﬂuenza strains, failed to show
ny signs of antigenic competition [54]. In addition, the large num-
er of skin APCs and the fast rate of repopulation within 24 h [45]
inimize the possibility of differences in the immune response
o inﬂuenza antigens when delivering either trivalent or quadri-
alent inﬂuenza vaccine. Taking under consideration the logistical
dvantages which this technology offers as well as the possibility of
dministering other pediatric vaccines, we consider this approach
o skin immunization to be a very promising vaccination strategy
hat will improve inﬂuenza-related outcomes in all age groups of
he population.
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